Company Profile:
Address: 10 BIOPOLIS RD 05 01, Singapore
Type of Business: Research and Development Center
Company Introduction:
The Experimental Drug Development Centre (EDDC) is Singapore's national platform for drug discovery and development, operating under the Agency for Science, Technology and Research (A*STAR). Situated at 10 Biopolis Road, it is a pivotal institution within Singapore's thriving biomedical sciences landscape. EDDC's core mission is to translate fundamental scientific breakthroughs into innovative drug candidates designed to address critical unmet medical needs.
EDDC engages in a comprehensive range of activities across the drug discovery and development pipeline. This includes target identification and validation, hit identification, lead optimization, preclinical development, and support for early-phase clinical trials. The center is equipped with cutting-edge facilities, employs advanced technologies, and boasts a multidisciplinary team of experts spanning chemistry, biology, pharmacology, and drug development. It actively fosters collaborations with academic institutions, healthcare providers, and pharmaceutical industry partners both locally and internationally to expedite the advancement of novel therapeutic solutions.
As an integral part of A*STAR, EDDC significantly contributes to enhancing Singapore's biomedical research capabilities, driving innovation, and participating in the global effort to combat diseases. Its work is instrumental in generating intellectual property, attracting foreign investment, and ultimately bringing new medicines to patients worldwide. EDDC's primary function is not large-scale drug manufacturing (factory) nor the commercial buying and selling of pharmaceutical products (trading company); rather, its focus is on the rigorous scientific process of discovering and developing potential new drugs.
Enterprise Products
Experimental Drug Development Centre (EDDC) under the Agency for Science, Technology and Research (A*STAR) is a national platform focused on drug discovery and development rather than a commercial entity that sells off-the-shelf products.
The organization focuses on the following activities and outputs:
1. Drug Discovery Pipeline
EDDC develops small molecule and biologic drug candidates targeting therapeutic areas such as oncology, infectious diseases, and inflammatory diseases.
2. Preclinical Development Services
It provides expertise and infrastructure for lead optimization, pharmacokinetics, toxicology, and process chemistry to advance drug candidates from discovery to clinical trials.
3. Intellectual Property and Licensing
It generates proprietary drug leads, novel chemical entities, and therapeutic platforms which are licensed to pharmaceutical companies, biotechnology firms, or used to spin off new ventures.
4. Collaborative Research Partnerships
It engages in co-development projects with academic institutions, clinical partners, and industry players to translate scientific research into potential clinical therapies.
5. Scientific Data and Methodologies
It produces research data, specialized assays, and validated protocols for drug screening and target validation.
In summary, EDDC produces clinical-stage drug candidates, therapeutic intellectual property, and research collaborations rather than consumer or retail products.